1. Home
  2. AVTX vs KPTI Comparison

AVTX vs KPTI Comparison

Compare AVTX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • KPTI
  • Stock Information
  • Founded
  • AVTX 2011
  • KPTI 2008
  • Country
  • AVTX United States
  • KPTI United States
  • Employees
  • AVTX N/A
  • KPTI N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVTX Health Care
  • KPTI Health Care
  • Exchange
  • AVTX Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • AVTX 88.4M
  • KPTI 81.1M
  • IPO Year
  • AVTX 2015
  • KPTI 2013
  • Fundamental
  • Price
  • AVTX $8.18
  • KPTI $0.63
  • Analyst Decision
  • AVTX Strong Buy
  • KPTI Strong Buy
  • Analyst Count
  • AVTX 4
  • KPTI 4
  • Target Price
  • AVTX $33.00
  • KPTI $5.00
  • AVG Volume (30 Days)
  • AVTX 65.8K
  • KPTI 694.6K
  • Earning Date
  • AVTX 03-28-2025
  • KPTI 02-27-2025
  • Dividend Yield
  • AVTX N/A
  • KPTI N/A
  • EPS Growth
  • AVTX N/A
  • KPTI N/A
  • EPS
  • AVTX N/A
  • KPTI N/A
  • Revenue
  • AVTX $820,000.00
  • KPTI $148,442,000.00
  • Revenue This Year
  • AVTX N/A
  • KPTI $5.47
  • Revenue Next Year
  • AVTX N/A
  • KPTI $6.33
  • P/E Ratio
  • AVTX N/A
  • KPTI N/A
  • Revenue Growth
  • AVTX N/A
  • KPTI 1.77
  • 52 Week Low
  • AVTX $4.17
  • KPTI $0.58
  • 52 Week High
  • AVTX $34.46
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 52.50
  • KPTI 46.51
  • Support Level
  • AVTX $7.82
  • KPTI $0.60
  • Resistance Level
  • AVTX $8.50
  • KPTI $0.70
  • Average True Range (ATR)
  • AVTX 0.78
  • KPTI 0.05
  • MACD
  • AVTX 0.20
  • KPTI -0.00
  • Stochastic Oscillator
  • AVTX 73.11
  • KPTI 46.61

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: